BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tzitzilis A, Boura‐theodorou A, Michail V, Papadopoulos S, Krikorian D, Lekka ME, Koukkou A, Sakarellos‐daitsiotis M, Panou‐pomonis E. Cationic amphipathic peptide analogs of cathelicidin LL‐37 as a probe in the development of antimicrobial/anticancer agents. J Pep Sci 2020;26. [DOI: 10.1002/psc.3254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu F, Zhu Y, Zhang G, Liu Z. Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy. Front Pharmacol 2022;13:944147. [DOI: 10.3389/fphar.2022.944147] [Reference Citation Analysis]
2 Tian T, Xie W, Liu L, Fan S, Zhang H, Qin Z, Yang C. Industrial application of antimicrobial peptides based on their biological activity and structure-activity relationship. Crit Rev Food Sci Nutr 2021;:1-16. [PMID: 34955061 DOI: 10.1080/10408398.2021.2019673] [Reference Citation Analysis]
3 Peel E, Cheng Y, Djordjevic JT, O'Meally D, Thomas M, Kuhn M, Sorrell TC, Huston WM, Belov K. Koala cathelicidin PhciCath5 has antimicrobial activity, including against Chlamydia pecorum. PLoS One 2021;16:e0249658. [PMID: 33852625 DOI: 10.1371/journal.pone.0249658] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Lin C, Wang Y, Le M, Chen KF, Jia YG. Recent Progress in Bile Acid-Based Antimicrobials. Bioconjug Chem 2021;32:395-410. [PMID: 33683873 DOI: 10.1021/acs.bioconjchem.0c00642] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Stergiou V, Krikorian D, Koukkou AI, Sakarellos-Daitsiotis M, Panou-Pomonis E. Novel anoplin-based (lipo)-peptide models show potent antimicrobial activity. J Pept Sci 2021;27:e3303. [PMID: 33506605 DOI: 10.1002/psc.3303] [Reference Citation Analysis]